Matt Gothard & Jared Quay discuss if they should bet against the Lakers during their 7-game road trip.
Matt Gothard & Jared Quay discuss if they should bet against the Lakers during their 7-game road trip.
The "Hong Kong Cards and Payments - Opportunities and Risks to 2024" report has been added to ResearchAndMarkets.com's offering.
National Gala also Honors Citi, the Citi Foundation and ASA NFTE's 2021 Entrepreneurial Spirit Awards Gala celebrated teachers, our frontline workers, and honored Citi, Citi Foundation, and American Student Assistance (ASA). New York, NY, March 05, 2021 (GLOBE NEWSWIRE) -- The theme of this year’s Network for Teaching Entrepreneurship’s (NFTE) Entrepreneurial Spirit Awards Gala, held online on March 4, 2021, was “Celebrating Teachers: NFTE’s Frontline Workers.” Sponsored by the nation’s leading nonprofit dedicated to advancing the entrepreneurial mindset in young people, the event celebrated the perseverance of NFTE teachers during the COVID-19 pandemic. A video montage shared messages of hope and appreciation from NFTE instructors, current NFTE students and alumni. NFTE also recognized Citi, the Citi Foundation, and American Student Assistance (ASA) with the Entrepreneurial Leadership Award for their dedication to the advancement of youth entrepreneurship education. “In the past year, the nation has seen just how essential our teachers are,” said Dr. J.D. LaRock, President and CEO of NFTE. “During the pandemic, teachers have had to confront all of the problems of society at once. They've had to teach the same content in half the time and do it while grappling with the very real issues of the digital divide. They’ve had to work with students who need more support than ever, and at times they’ve even had to work in situations where their own health could be compromised. We cannot underestimate the extent of their dedication in a time like this.” Over the last several years, hundreds of Citi team members have committed over 3,000 hours as coaches and mentors to budding NFTE entrepreneurs. With its Pathways to Progress initiative, the Citi Foundation has committed time and resources to address the global problem of youth unemployment and has become a leader in promoting youth entrepreneurship, job access, mentorship, financial education, and career guidance. “With so much happening in the world today, the Citi Foundation is accepting this not as an acknowledgment of the work we have done, but as a reminder of the work ahead of us, with all its challenges – and, yes, the opportunities,” said Brandee McHale, Head of Community Investing and Development at Citi and President of the Citi Foundation. “We are ready to take on this work alongside all of you: the youth, teachers and volunteers that bring NFTE’s vision to life.” Likewise, American Student Assistance (ASA) has focused on helping students access educational opportunities for more than 60 years. Through philanthropy, advocacy, research, and collaborations with partners like NFTE, ASA continues to help middle and high school students know themselves, know their options and make informed choices about their education and career goals. “Students are naturally curious and innovative in their own ways, and entrepreneurial programs teach students how to harness that creativity to launch a new business or endeavor,” said ASA President and CEO Jean Eddy. “Through these programs, educators are helping students learn about the range of jobs and occupations available and build their occupational identity and entrepreneurial mindset that will serve these students well into the future. We are proud to support these hardworking and dedicated NFTE educators and their students.” In addition to the honorees, the Gala celebrated the leadership of former and current board members with the Lowell B. Mason Award for Exemplary Board Leadership, named for NFTE founder Steve Mariotti’s grandfather. The recipients were National Board chair Michael J. Kacsmar, of EY, Board member Gus Harris, recently of Moody’s Analytics, and former longtime Board member Diana Davis Spencer, executive chairman of her eponymous foundation. The event was emceed by NFTE alumnus Aaron Trinidad, winner of the 2019 National Youth Entrepreneurship Challenge. Aaron attends DePauw University and is currently working with the Chicago-based startup Jiobit. About NFTE Network for Teaching Entrepreneurship (NFTE) is a global nonprofit organization that provides high-quality entrepreneurship education to middle and high school students from under-resourced communities, as well as programs for college students and adults. NFTE reaches 70,000+ students annually in 25 states across the U.S. and offers programs in 12 additional countries. We have educated more than a million students through in-school, out-of-school, college, and summer camp programs, offered in person and online. To learn more about how we are promoting inclusive capitalism and building the next generation of diverse entrepreneurs, visit www.nfte.com. Attachment NFTE-Entrepreneurial-Spirit-Awards-Gala-2021 CONTACT:
The "2021 Organic Sesame Seed Market - Size, Share, COVID Impact Analysis and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
ThinkWhy, a SaaS company helping businesses navigate the labor market, released its national jobs report following an announcement from the Bureau of Labor Statistics that the economy added 379,000 jobs in February, with the unemployment rate at 6.2 percent.
An Iowa journalist faces trial Monday on charges stemming from her coverage of a protest against racial injustice, a case that prosecutors have pursued despite international condemnation from free press advocates who say she was just doing her job. The case of Des Moines Register reporter Andrea Sahouri, who was pepper sprayed and arrested while reporting on a clash between protesters and police, will highlight an aggressive response by Iowa authorities against those who organized and attended protests that erupted last summer and occasionally turned violent. Sahouri and her former boyfriend are charged with failure to disperse and interference with official acts, misdemeanors that could bring fines and up to 30 days in jail.
Welcome to Atlanta, home of High Water — the city's most competitive performing arts school. When twins Tal and Janelle relocate from Ohio, they find themselves thrust into a world where every move is a test. As they attempt to navigate their new world— on and off the dance floor— they’ll discover just how deep they’re willing to dig to realize their dreams and seize their moment.
The "Audio Surveillance Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
Shares of Norwegian Cruise Line Holdings Ltd. tumbled 10.0% in morning trading Friday, after the cruise operator said its public offering of 47.58 million shares priced $30 a share. That price was 8.8% below Thursday's closing price of $32.90. The share offering represents 15.1% of the shares outstanding as of Feb. 16. The company said it plans to use the proceeds from the offering to repurchase all of its subsidiary NCL Corp. Ltd.'s exchangeable senior notes due 2026 currently held by an L Catterton affiliate, with any remaining proceeds to be used for general corporate purposes. The company's cruises remain suspended through May 31 as a result of the COVID-19 pandemic. Norwegian's stock, which closed Wednesday at a one-year high, has rallied 12.6% over the past three months, while the S&P 500 has gained 2.3%.
Rwanda began its COVID-19 vaccine campaign on Friday, becoming the first nation in Africa to use pharmaceutical company Pfizer's doses that require ultra-cold storage. Authorities began transporting Pfizer and AstraZeneca shots round the hilly nation of 12 million people after they arrived earlier this week, using helicopters to reach far-flung parts. "This means that I will die when God wants because the coronavirus cannot kill me now," 90-year-old Stephanie Nyirankuriza said, leaning on a walking stick after her shot at a health centre just east of the capital Kigali.
The Dow Jones Industrial Average surged 300 points after Friday's strong jobs report, as yields jumped. Tesla stock looked to rebound from heavy losses.
It was Andrew Cuomo’s Emmy-winning performance: daily televised coronavirus briefings in which the New York governor projected competence and compassion, helping to calm a nervous nation. Now, the many Americans whose positive impressions of Cuomo were formed during the height of the pandemic are getting a close-up of a very different governor, one accused of underreporting COVID-19 deaths in nursing homes, sexually harassing female staffers and bullying colleagues. To New Yorkers who have watched the Democrat for years, however, the allegations are consistent with how Cuomo maintains his tight grip on power.
Wolves were the first to be penalised after the last handball rule change.
The economy added 379,000 jobs in February and unemployment fell to 6.2%
Disney's first new movie of 2021, Raya and the Last Dragon, is finally here after being pushed off the release schedule in 2020! The beautifully animated movie, which features Disney's first Southeast Asian princess (voiced by Star Wars's Kelly Marie Tran), tells a story that centers on trust, teamwork, and coming together with those you differ from in pursuit of a greater good.
Lysol kills 99.9 percent of germs and bacteria on household surfaces—score disinfectant spray, multi-surface cleaner and more.
(Bloomberg) -- Chamath Palihapitiya, the billionaire investor who has helped drive the frenzied growth of blank-check companies, sold his personal holding in the space-tourism company founded by Richard Branson, raising $213 million.Palihapitiya disposed of 6.2 million shares at an average price of $34.32 this week, based on a filing with the U.S. Securities and Exchange Commission. He still owns 15.8 million shares with his partner Ian Osborne through investment firm Social Capital Hedosophia, amounting to about a 6.5% stake. Palihapitiya previously sold shares worth almost $100 million in December, filings show.Read more: The king of SPACs wants you to know he’s the next Warren BuffettVirgin Galactic’s shares have increased about 150% since the Las Cruces, New Mexico-based company merged with Social Capital’s first SPAC in 2019. The stock though has slid almost 50% from a peak last month and was down 4.9% to $28.81 at 9:33 a.m. in New York.Palihapitiya has since launched blank-check companies that have merged with businesses across health insurance, financial services and real estate including Opendoor Technologies Inc. and Clover Health Investments Corp.Along the way, 44-year-old Palihapitiya has made a fortune for himself and his investors. The former Facebook Inc. executive has raised more than $4 billion through blank-check firms, using social media to talk up the investments and becoming one of the most prominent figures in the SPAC phenomenon, which has everyone from Colin Kaepernick to former House Speaker Paul Ryan racing to market their own.He’s also a lightning rod for skeptics who dismiss his success as the product of self-promotion and see blank-check companies as proof of a bubble inflated by government money-printing.A month ago, Palihapitiya said it would only be under the rarest of circumstances that he’d reduce his holdings of any SPAC.“If I could really just go for it, I wouldn’t sell a share of anything I buy because I believe in it,” he said Feb. 8 in a interview on Bloomberg Television’s “Front Row.” “But every now and then, I run into liquidity constraints, like everybody else.”At the time, Palihapitiya had just recently sold 3.8 million Virgin Galactic shares. He said he did so because his family office called needing cash for other purposes.Shares DropSocial Capital’s merger with Virgin Galactic -- where Palihapitiya is chairman -- made the Branson startup the world’s first publicly traded space-travel venture. The transaction raised about $800 million, with Palihapitiya also directly contributing $100 million.While the shares surged in the wake of the listing, they have dropped 49% since a February decision to delay the next flight to space. The new schedule also pushed back plans to carry Branson, 70, on a separate mission in the first quarter. Virgin Galactic has a current market value of $7.2 billion.The company on Thursday announced the departure of its chief space officer, George Whitesides, saying he has decided to pursue potential opportunities in public service. Whitesides, who served as chief executive officer for a decade until July 2020, will remain chairman of a four-person Space Advisory Board.Though Virgin Galactic has hundreds of clients lined up to pay at least $250,000 for a 90-minute flight to the edge of space, it has been a slow journey since the venture was founded in 2004. Plans were put on hold for four years in 2014 after a space plane broke up mid-flight, killing one pilot and injuring another.(Updates with share price in third paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Olsen's famous older sisters, Mary-Kate and Ashley Olsen, starred in the beloved sitcom with Stamos.
Data: FRED; Chart: Axios VisualsGood news for your Friday: the economy added a whopping 379,000 jobs in February — far outpacing expectations. Why it matters: Virus cases eased in recent weeks and states lifted restrictions, helping fuel a hiring surge. It's proof of how much control the pandemic has over the job market.Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for freeThe clearest signal: The bounce-back was largely driven by hiring in the leisure and hospitality sectors, which came even in the dead of winter. This sector is a key example of one that can't recover until people feel safe eating and drinking out.Here's the bad news: Job growth peaked with 152.5 million payrolls before the pandemic hit the labor market.Even with today's report — the best jobs growth since October — we're still more than 9 million jobs below that level one year later.And despite the big gains in leisure and hospitality, the sector still has 20% fewer jobs.The number of workers who have been unemployed for 27 weeks or more — 4.1 million — barely budged.Between the lines: President Biden was handed a labor market hobbled by a pandemic. Its recovery hinges on keeping COVID cases low, succeeding with mass vaccination, and getting hard-hit businesses to return to hiring. "February was OK but at that pace, [it] would take 4 1/2 years to recover. We need more like 1m jobs a month," Jason Furman, a former economic adviser in the Obama administration, tweeted.The jobs figures in January and February also came in the wake of improving case numbers and a $900 billion relief bill passed in December, Furman noted. The Senate is currently debating Biden's $1.9 trillion rescue package.The bottom line: Economists are penciling in a "Roaring 20s"-like recovery — with eye-popping growth figures to boot! — as vaccines continue to roll out and the economy opens up.A pessimistic parting shot, courtesy of the Federal Reserve chair: "We have significant ground to cover," Jerome Powell said yesterday, cautioning that a complete job market healing likely won't come this year.Like this article? Get more from Axios and subscribe to Axios Markets for free.
The drug discovery market is expected to register a CAGR of nearly 8. 3% during the forecast period, with a revenue of approximately USD 53,855 million in 2020, and it is expected to reach 85,785 million by 2026.New York, March 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Drug Discovery Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" - https://www.reportlinker.com/p06030454/?utm_source=GNW Amid the COVID-19 pandemic, the health system of countries is rapidly investing in research and development to combat the virus. Potential compounds were screened from the CHEMBL database, ZINC database, FDA approved drugs, and molecules under clinical trials. Research groups across the world are identifying drugs for the treatment of COVID-19, by screening both novel and existing drugs for their ability to alleviate symptoms and stem viral replication. Thus, in view of the ongoing pandemic, the drug discovery market is expected to be positively impacted by the urge to find a cure for COVID-19.The propelling factors for the growth of the drug discovery market include the rising burden of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and upcoming patent expiration of blockbuster drugs.Cardiovascular diseases, infectious diseases, diabetes, and kidney-related complications have high burden, globally. For instance, according to the estimates of the Heart Disease and Stroke Statistics 2019, approximately 116.4 million, or 46% of adults in the United States were estimated to have hypertension.Also, according to the American Cancer Society, in 2020, about 1.8 million new cancer cases are expected to be diagnosed, and approximately 606,520 cancer deaths may occur in the United States. Thus, the increasing burden of a diverse range of diseases among all age groups and its burden, globally, drive the demand for drug discovery and its market.There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics, and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. The adoption of artificial intelligence systems in disease diagnostics and treatment design started growing, and this is expected to witness robust growth in the coming years. For instance, on March 31, 2020, Existencia, an AI-based drug discovery company, entered a collaborative agreement with Diamond Light Source and Scripps Research for identifying COVID-19 antiviral therapies. It is anticipated to contribute to the growth of the market over the forecast period.The gradual rise in the healthcare expenditure regionally helps the new pharmaceutical technology advancement. Although with high expenditure, there is a need for redirecting the resources.Key Market TrendsBiologics Drug is the Segment that is Expected to Grow Fastest Under Drug TypeBiologics and drugs offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure the diseases rather than merely treat the symptoms, which significantly increased the demand for these products.?The efficacy and safety of biopharmaceuticals have led to their rapid adoption by people, driving the global drug discovery market. As per the report of Pharmaceutical Research and Manufacturers of America 2019, biopharmaceutical products have shown positive results for some of the chronic and rare diseases, which led to its sharp rise in the demand.As per the study of Journal of Family Medicine and Primary care 2020, about 12 out of 46 drugs were anticancer agents in 2017, and in 2018, about 23 out of 55 were anticancer drugs.As per the same study, the number of New Drug Applications (NDAs)/Biologic License Applications (BLA’s) registered per year has seen a significant increase over the past decade. In 2017, around 46 agents were approved, while in 2018, around 59 novel agents were approved. Therefore, it is expected to further drive the market studied over the forecast period.In the pandemic, the rising adoption of biologics due to the certain advantages associated with them, especially target specificity, is boding well for the market studied. A significant number of major biotech firms are in the middle of a race to investigate the Sars-Cov-2 genome and prepare therapeutics for the same. For instance, in November 2020, South Korean pharma company Samsung Biologics entered a long-term agreement with Eli Lilly and Company to manufacture its investigational COVID-19 virus-neutralizing antibody, bamlanivimab.?Therefore, it is expected to further drive the market studied over the forecast period.North America is Expected to Hold the Largest Market Share Over the Forecast PeriodNorth America leads the world in terms of R&D spending on pharmaceuticals. It is also the largest market for bulk drugs and finished dosage formulations. The market operates as a free economy, which is designed to implement transparent trade practices and restrict anti-competitive practices.??A major push for generic drugs and biosimilars is expected to boost the demand for specialty and complex ingredients, over the forecast period. ?For instance, in 2019, Biocon and Mylan jointly launched a cancer drug called Ogivri, a biosimilar to Herceptin, in the United States. Herceptin is a biologic therapeutic used for the treatment of all types of breast cancers and metastatic stomach cancers (gastric or gastroesophageal junction adenocarcinoma). ?Also, in November 2019, Genesis Therapeutics announced that it raised USD 4.1 million in seed funding led by Andreessen Horowitz. This company is harnessing breakthrough AI-technology to optimize drug discovery and development.Furthermore, the country has great opportunities for biosimilars, as biologics carry higher price. By 2020, the US market is estimated to become one of the major competitors of biosimilars. The key products in the US market are Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, etc. Hence, owing to the aforementioned factors, the market is estimated to witness a high growth over the forecast period.The COVID-19 pandemic highlighted the need for North American companies and research organizations to collaborate with the government to develop new drugs, in order to meet future health crises. Several universities and key players are focusing on developing vaccines for coronavirus. For instance, Eli Lilly partnered with AbCellera for the development of vaccines. Thus, this is expected to further boost the market studied over the forecast period.Competitive LandscapeThe market studied has various pharmaceutical companies that are investing billions of dollars in artificial intelligence (AI), in order to make the drug discovery process significantly faster and cost-efficient. The pharmaceutical and biotech companies are increasing their collaborations with contract development and manufacturing organizations.Reasons to Purchase this report:- The market estimate (ME) sheet in Excel format- 3 months of analyst supportRead the full report: https://www.reportlinker.com/p06030454/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
(Bloomberg) -- Stocks rose after a surprisingly strong jobs report added to evidence the economic recovery in gaining momentum. Treasuries fell.Traders shrugged off anxiety about the economy running too hot and fueling inflation, with the S&P 500 rebounding from a five-week low. U.S. employers added more jobs than forecast in February and the unemployment rate declined, suggesting the labor market is clawing its way forward again following several disappointing months. Benchmark 10-year bond yields pared an earlier surge after hitting 1.6%. The dollar rose.Treasury yields have spiked in recent weeks on mounting expectations of stronger economic growth and faster inflation, unsettling the stock market, particularly shares of high-flying technology companies. Federal Reserve Chairman Jerome Powell left investors underwhelmed by his comments on the bond market Thursday. While he did reaffirm the central bank’s commitment to remaining accommodative, he did not try to rein in the selloff.For equity markets, “evidence of a strengthening economy may help steady the nerves,” said Seema Shah, chief strategist at Principal Global Investors. “Does the Fed have the credibility to keep a rein on bond yields? With real yields steadily making their way up to zero, the Fed is slowly running out of time to prove its resolve and commitment to its average inflation target. Until it does, each piece of positive economic news may only serve to disrupt both bond and equity markets.”Read: Momentum Quants Will Unleash the ‘Most Turbulent Rebalance Ever’These are some of the main moves in markets:StocksThe S&P 500 climbed 0.5% as of 9:39 a.m. New York time.The Stoxx Europe 600 Index was little changed.The MSCI Asia Pacific Index dipped 0.7%.The MSCI Emerging Market Index declined 0.8%.CurrenciesThe Bloomberg Dollar Spot Index climbed 0.2%.The euro dipped 0.4% to $1.1921.The Japanese yen depreciated 0.4% to 108.40 per dollar.BondsThe yield on 10-year Treasuries climbed two basis points to 1.59%.Germany’s 10-year yield advanced two basis points to -0.29%.Britain’s 10-year yield increased five basis points to 0.776%.CommoditiesWest Texas Intermediate crude climbed 2.4% to $65.39 a barrel.Gold strengthened 0.1% to $1,698.85 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.